{"id":3623,"date":"2025-03-31T18:11:46","date_gmt":"2025-03-31T18:11:46","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/acamprosate-calcium-txt\/"},"modified":"2025-03-31T18:11:46","modified_gmt":"2025-03-31T18:11:46","slug":"acamprosate-calcium-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/acamprosate-calcium-txt\/","title":{"rendered":"ACAMPROSATE CALCIUM.txt"},"content":{"rendered":"

ACAMPROSATE CALCIUM<\/h1>\n

CLINICAL USE <\/H3>Maintenance of abstinence in alcohol dependence

DOSE IN NORMAL RENAL FUNCTION <\/H3><\/p>\n
  • <60 kg: 666 mg 3 times a day\n
  • >60 kg: 666 mg at breakfast, 333 mg at midday and 333 mg at night

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :400.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Majority<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :Approximately 1<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :33\/85.8

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 333 mg 3 times daily10\u201330 333 mg twice daily
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 333 mg once daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=10\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>\n
  • Recommended treatment period is a year\n
  • After a single dose of 666 mg in patients with severe renal impairment, the average maximum concentration was 4 times that in healthy individuals\n
  • Bioavailability is reduced if administered with food
    \n","protected":false},"excerpt":{"rendered":"

    ACAMPROSATE CALCIUM CLINICAL USE Maintenance of abstinence in alcohol dependence<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3623","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3623"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3623\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}